JP2010528994A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010528994A5 JP2010528994A5 JP2010509700A JP2010509700A JP2010528994A5 JP 2010528994 A5 JP2010528994 A5 JP 2010528994A5 JP 2010509700 A JP2010509700 A JP 2010509700A JP 2010509700 A JP2010509700 A JP 2010509700A JP 2010528994 A5 JP2010528994 A5 JP 2010528994A5
- Authority
- JP
- Japan
- Prior art keywords
- het
- atoms
- group
- formula
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 210000003128 head Anatomy 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- -1 1,3-dihydrobenzimidazolyl Chemical group 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 230000002152 alkylating effect Effects 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 238000004517 catalytic hydrocracking Methods 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000004324 lymphatic system Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102007025717A DE102007025717A1 (de) | 2007-06-01 | 2007-06-01 | Arylether-pyridazinonderivate |
| DE102007025717.3 | 2007-06-01 | ||
| PCT/EP2008/003549 WO2008145242A1 (de) | 2007-06-01 | 2008-05-02 | Arylether-pyridazinonderivate |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010528994A JP2010528994A (ja) | 2010-08-26 |
| JP2010528994A5 true JP2010528994A5 (OSRAM) | 2011-06-23 |
| JP5385262B2 JP5385262B2 (ja) | 2014-01-08 |
Family
ID=39669858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010509700A Expired - Fee Related JP5385262B2 (ja) | 2007-06-01 | 2008-05-02 | アリールエーテルピリダジノン誘導体 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8445489B2 (OSRAM) |
| EP (1) | EP2152370B1 (OSRAM) |
| JP (1) | JP5385262B2 (OSRAM) |
| KR (1) | KR20100027182A (OSRAM) |
| CN (1) | CN101678214B (OSRAM) |
| AR (1) | AR066769A1 (OSRAM) |
| AT (1) | ATE515289T1 (OSRAM) |
| AU (1) | AU2008255327B2 (OSRAM) |
| BR (1) | BRPI0812295A2 (OSRAM) |
| CA (1) | CA2688517C (OSRAM) |
| DE (1) | DE102007025717A1 (OSRAM) |
| DK (1) | DK2152370T3 (OSRAM) |
| EA (1) | EA200901603A1 (OSRAM) |
| ES (1) | ES2367152T3 (OSRAM) |
| IL (1) | IL202373A (OSRAM) |
| MX (1) | MX2009012709A (OSRAM) |
| PL (1) | PL2152370T3 (OSRAM) |
| PT (1) | PT2152370E (OSRAM) |
| WO (1) | WO2008145242A1 (OSRAM) |
| ZA (1) | ZA200909055B (OSRAM) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5335675B2 (ja) * | 2006-07-25 | 2013-11-06 | セファロン、インク． | ピリジジノン誘導体 |
| DE102008062826A1 (de) * | 2008-12-23 | 2010-07-01 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102009003954A1 (de) * | 2009-01-07 | 2010-07-08 | Merck Patent Gmbh | Pyridazinonderivate |
| US20130315895A1 (en) | 2010-07-01 | 2013-11-28 | Takeda Pharmaceutical Company Limited | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET |
| US8703953B2 (en) * | 2012-03-09 | 2014-04-22 | Bristol-Myers Squibb Company | Aryl ether-base kinase inhibitors |
| MX2014015156A (es) | 2012-06-12 | 2015-08-06 | Abbvie Inc | Derivados de piridinona y piridazinona. |
| EP2922543B1 (en) * | 2012-11-20 | 2017-05-24 | Merck Sharp & Dohme Corp. | Substituted pyridone derivatives as pde10 inhibitors |
| US9567320B2 (en) * | 2013-02-07 | 2017-02-14 | Merck Patent Gmbh | Pyridazinone-amides derivatives |
| WO2014159776A1 (en) * | 2013-03-14 | 2014-10-02 | Cephalon, Inc. | Solid state forms of 6-[4-[3-(r)-2-methylpyrrolidine-1-yl)-propoxy]phenyl]2h-pyridazine-3-one hydrochloride |
| ES2764299T3 (es) | 2014-12-09 | 2020-06-02 | Inst Nat Sante Rech Med | Anticuerpos monoclonales humanos contra AXL |
| WO2016135041A1 (en) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
| AU2016341445B2 (en) | 2015-10-23 | 2020-08-27 | Array Biopharma, Inc. | 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases |
| US20190248765A1 (en) * | 2016-10-26 | 2019-08-15 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
| EP4248972A3 (en) | 2018-11-06 | 2023-12-06 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
| WO2020097258A1 (en) * | 2018-11-06 | 2020-05-14 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
| DK3877376T3 (da) | 2018-11-06 | 2023-10-02 | Edgewise Therapeutics Inc | Pyridazinonforbindelser og anvendelser deraf |
| EP3898626A1 (en) | 2018-12-19 | 2021-10-27 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
| JP2022515197A (ja) | 2018-12-19 | 2022-02-17 | アレイ バイオファーマ インコーポレイテッド | がんを治療するためのｆｇｆｒ阻害剤としての７－（（３，５－ジメトキシフェニル）アミノ）キノキサリン誘導体 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5795964A (en) | 1980-12-04 | 1982-06-15 | Morishita Seiyaku Kk | Preparation of 2-substituted-3(2h)-pyridazinone derivative |
| US4397854A (en) | 1981-05-14 | 1983-08-09 | Warner-Lambert Company | Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents |
| CN1038249C (zh) * | 1991-08-28 | 1998-05-06 | 罗姆和哈斯公司 | 含有二氢哒嗪酮及其相关化合物的杀菌组合物 |
| AU691673B2 (en) | 1994-11-14 | 1998-05-21 | Dow Agrosciences Llc | Pyridazinones and their use as fungicides |
| US5635494A (en) | 1995-04-21 | 1997-06-03 | Rohm And Haas Company | Dihydropyridazinones and pyridazinones and their use as fungicides and insecticides |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| WO1997030035A1 (en) | 1996-02-13 | 1997-08-21 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| PT885198E (pt) | 1996-03-05 | 2002-06-28 | Astrazeneca Ab | Derivados de 4-anilinoquinazolina |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| NZ504045A (en) | 1997-11-19 | 2001-06-29 | Kowa Co | Pyridazine derivatives with inhibitory action against interleukin-1-beta production |
| TWI241295B (en) | 1998-03-02 | 2005-10-11 | Kowa Co | Pyridazine derivative and medicine containing the same as effect component |
| HK1041876B (en) * | 1998-10-27 | 2006-06-23 | Abbott Laboratories | Prostaglandin endoperoxide h synthase biosynthesis inhibitors |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| AU2001258628A1 (en) | 2000-05-31 | 2001-12-11 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| BR0112225A (pt) | 2000-07-07 | 2003-05-06 | Angiogene Pharm Ltd | Composto, composição farmacêutica, uso de um composto, e, processo papa preparar um composto |
| MXPA02012905A (es) | 2000-07-07 | 2004-07-30 | Angiogene Pharm Ltd | Derivados de colquinol como agentes de dano vascular.. |
| EP1463509A1 (en) | 2001-10-31 | 2004-10-06 | MERCK PATENT GmbH | Type 4 phosphodiesterase inhibitors and uses thereof |
| DE10349587A1 (de) | 2003-10-24 | 2005-05-25 | Merck Patent Gmbh | Benzimidazolylderivate |
| DE102005057924A1 (de) * | 2005-12-05 | 2007-06-06 | Merck Patent Gmbh | Pyridazinonderivate |
| JP5335675B2 (ja) * | 2006-07-25 | 2013-11-06 | セファロン、インク． | ピリジジノン誘導体 |
| DE102006037478A1 (de) * | 2006-08-10 | 2008-02-14 | Merck Patent Gmbh | 2-(Heterocyclylbenzyl)-pyridazinonderivate |
-
2007
- 2007-06-01 DE DE102007025717A patent/DE102007025717A1/de not_active Withdrawn
-
2008
- 2008-05-02 CA CA2688517A patent/CA2688517C/en active Active
- 2008-05-02 DK DK08749296.3T patent/DK2152370T3/da active
- 2008-05-02 CN CN200880018485XA patent/CN101678214B/zh not_active Expired - Fee Related
- 2008-05-02 ES ES08749296T patent/ES2367152T3/es active Active
- 2008-05-02 MX MX2009012709A patent/MX2009012709A/es active IP Right Grant
- 2008-05-02 KR KR1020097027511A patent/KR20100027182A/ko not_active Withdrawn
- 2008-05-02 AT AT08749296T patent/ATE515289T1/de active
- 2008-05-02 PT PT08749296T patent/PT2152370E/pt unknown
- 2008-05-02 WO PCT/EP2008/003549 patent/WO2008145242A1/de not_active Ceased
- 2008-05-02 BR BRPI0812295-4A2A patent/BRPI0812295A2/pt not_active IP Right Cessation
- 2008-05-02 JP JP2010509700A patent/JP5385262B2/ja not_active Expired - Fee Related
- 2008-05-02 EA EA200901603A patent/EA200901603A1/ru unknown
- 2008-05-02 AU AU2008255327A patent/AU2008255327B2/en not_active Ceased
- 2008-05-02 US US12/602,284 patent/US8445489B2/en not_active Expired - Fee Related
- 2008-05-02 PL PL08749296T patent/PL2152370T3/pl unknown
- 2008-05-02 EP EP08749296A patent/EP2152370B1/de not_active Not-in-force
- 2008-05-30 AR ARP080102270A patent/AR066769A1/es unknown
-
2009
- 2009-11-26 IL IL202373A patent/IL202373A/en active IP Right Grant
- 2009-12-18 ZA ZA200909055A patent/ZA200909055B/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010528994A5 (OSRAM) | ||
| JP2010529051A5 (OSRAM) | ||
| JP2011518202A5 (OSRAM) | ||
| JP2019519491A5 (OSRAM) | ||
| JP2014502599A5 (OSRAM) | ||
| JP2011530545A5 (OSRAM) | ||
| JP2010528995A5 (OSRAM) | ||
| RU2014115847A (ru) | Пирролопиримидиновые соединения для лечения злокачественной опухоли | |
| JP2019513734A5 (OSRAM) | ||
| JP2012509349A5 (OSRAM) | ||
| JP2009519243A5 (OSRAM) | ||
| JP2009545534A5 (OSRAM) | ||
| JP2018511590A5 (OSRAM) | ||
| JP2011517453A5 (OSRAM) | ||
| CN107428772B (zh) | 盐霉素的含氮类似物、合成及抗癌干细胞和疟疾的用途 | |
| HRP20220886T1 (hr) | Pripravci i postupci za proizvodnju pirimidina i spojeva piridina s btk inhibicijskom aktivnošću | |
| HRP20110807T1 (hr) | Supstituirani pirimidodiazepini korisni kao plk1 inhibitori | |
| JP2016519062A5 (OSRAM) | ||
| HRP20240582T1 (hr) | Spojevi korisni za liječenje raka | |
| RU2013140169A (ru) | Противоопухолевое терапевтическое средство | |
| JP2015535831A5 (OSRAM) | ||
| JPWO2020123827A5 (OSRAM) | ||
| JP2019504833A5 (OSRAM) | ||
| JP2014519507A5 (OSRAM) | ||
| JP2012522841A5 (OSRAM) |